- Home
- BBU vs OGN Comparison
BBU vs OGN Comparison
Compare BBU & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBU
- OGN
- Stock Information
- Founded
- BBU 2016
- OGN 1923
- Country
- BBU Bermuda
- OGN United States
- Employees
- BBU N/A
- OGN N/A
- Industry
- BBU Engineering & Construction
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- BBU Consumer Discretionary
- OGN Health Care
- Exchange
- BBU Nasdaq
- OGN Nasdaq
- Market Cap
- BBU 2.4B
- OGN 2.7B
- IPO Year
- BBU N/A
- OGN N/A
- Fundamental
- Price
- BBU $27.70
- OGN $10.85
- Analyst Decision
- BBU Buy
- OGN Buy
- Analyst Count
- BBU 5
- OGN 3
- Target Price
- BBU $31.80
- OGN $17.33
- AVG Volume (30 Days)
- BBU 36.3K
- OGN 3.6M
- Earning Date
- BBU 11-07-2025
- OGN 10-30-2025
- Dividend Yield
- BBU 0.91%
- OGN 0.74%
- EPS Growth
- BBU N/A
- OGN N/A
- EPS
- BBU N/A
- OGN 2.69
- Revenue
- BBU $30,103,000,000.00
- OGN $6,281,000,000.00
- Revenue This Year
- BBU N/A
- OGN N/A
- Revenue Next Year
- BBU $5.85
- OGN $0.82
- P/E Ratio
- BBU N/A
- OGN $4.03
- Revenue Growth
- BBU N/A
- OGN N/A
- 52 Week Low
- BBU $18.63
- OGN $8.01
- 52 Week High
- BBU $28.28
- OGN $20.58
- Technical
- Relative Strength Index (RSI)
- BBU 56.60
- OGN 67.22
- Support Level
- BBU $26.83
- OGN $10.24
- Resistance Level
- BBU $28.10
- OGN $10.95
- Average True Range (ATR)
- BBU 0.86
- OGN 0.41
- MACD
- BBU -0.07
- OGN 0.08
- Stochastic Oscillator
- BBU 77.78
- OGN 94.54
About BBU Brookfield Business Partners L.P. Limited Partnership Units
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.